Liwu Fu
Impact in
- Oncology top 0.5%
- Drug Transport and Resistance Mechanisms
- Cancer Cells and Metastasis
- Cancer Research top 1%
- MicroRNA in disease regulation
Papers in
- Oncology 115
- Drug Transport and Resistance Mechanisms 77
- Cancer Cells and Metastasis 10
-
- Cancer therapeutics and mechanisms 36
- RNA Interference and Gene Delivery 13
- Co-authors
- Fang Wang (48 shared papers)Kenneth K.W. To (48 shared papers)Zhe‐Sheng Chen (40 shared papers)Lihua Huang (2 shared papers)Yong‐ju Liang (42 shared papers)Zhixing Guo (5 shared papers)Lamei Huang (5 shared papers)Sainan An (6 shared papers)
- Journals
- Molecular Cancer (12 papers)Cancer Research (10 papers)Acta Pharmaceutica Sinica B (10 papers)Biochemical Pharmacology (10 papers)Oncotarget (7 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Liwu Fu
206 papers receiving 11.4k citations
Liwu Fu's Hit Papers
Peers
Comparison fields: 5 of 141
- Oncology 4.9k
- Cancer Research 1.3k
- Molecular Biology 5.5k
- Toxicology 173
- Hematology 468
Countries citing papers authored by Liwu Fu
This map shows the geographic impact of Liwu Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liwu Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liwu Fu more than expected).
Fields of papers citing papers by Liwu Fu
This network shows the impact of papers produced by Liwu Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liwu Fu. The network helps show where Liwu Fu may publish in the future.
Co-authors
The 25 scholars most cited alongside Liwu Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 211 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | KRAS mutation: from undruggable to druggable in cancer Hit paper breakdown → | 2021 | 755 |
| 2 | Mechanisms of resistance to EGFR tyrosine kinase inhibitors Hit paper breakdown → | 2015 | 493 |
| 3 | 2009 | 355 | |
| 4 | 2008 | 350 | |
| 5 | 2006 | 299 | |
| 6 | 2010 | 299 | |
| 7 | 2018 | 298 | |
| 8 | CD39/CD73/A2AR pathway and cancer immunotherapy Hit paper breakdown → | 2023 | 274 |
| 9 | Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance Hit paper breakdown → | 2022 | 273 |
| 10 | 2007 | 270 | |
| 11 | 2017 | 192 | |
| 12 | Targeting cancer stem cells: a new therapy to cure cancer patients. | 2012 | 177 |
| 13 | 2016 | 168 | |
| 14 | 2011 | 156 | |
| 15 | 2002 | 140 | |
| 16 | 2004 | 137 | |
| 17 | 2014 | 135 | |
| 18 | 2006 | 132 | |
| 19 | 2014 | 128 | |
| 20 | 2022 | 121 |
About Liwu Fu
Liwu Fu is a scholar working on Oncology, Molecular Biology, Cancer Research, Hematology and Infectious Diseases, having authored 211 papers that have together received 11.6k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (77 papers), Cancer therapeutics and mechanisms (36 papers), HIV/AIDS drug development and treatment (16 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers), RNA Interference and Gene Delivery (13 papers), Chronic Myeloid Leukemia Treatments (13 papers), Synthesis and biological activity (11 papers) and Cancer Cells and Metastasis (10 papers). The work is most often cited by research in Oncology (4.9k citations), Cancer Research (1.3k citations), Molecular Biology (5.5k citations), Toxicology (173 citations) and Hematology (468 citations). Liwu Fu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Fang Wang, Kenneth K.W. To, Zhe‐Sheng Chen, Lihua Huang, Yong‐ju Liang, Zhixing Guo, Lamei Huang, Sainan An, Jian-ye Zhang and Chun-ling Dai. Their work appears in journals such as Molecular Cancer, Cancer Research, Acta Pharmaceutica Sinica B, Biochemical Pharmacology and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.